Processa Pharmaceuticals, Inc. Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted
Processa Pharmaceuticals, Inc. (PCSA) reported Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted of -$1.86 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-04-16.
Discontinued › Income Statement › Other Income
us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted · last filed 2018-04-16
- Processa Pharmaceuticals, Inc. net income (loss) from continuing operations available to common shareholders, diluted for fiscal 2017 was -$1.86M.
- Processa Pharmaceuticals, Inc. net income (loss) from continuing operations available to common shareholders, diluted for fiscal 2016 was -$1.92M.
| Period end | Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted 12 month |
|---|---|
| 2017-12-31 | -$1.86M 10-K · filed 2018-04-16 |
| 2016-12-31 | -$1.92M 10-K · filed 2018-04-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |